Therapeutic agent for muscle atrophy, and screening method
Targeting Mkl1 and Mkl2 to inhibit Foxo transcription factors addresses the challenge of muscle atrophy by enhancing their expression or stability, effectively treating and preventing muscle atrophy across various causes, as evidenced by increased muscle weight and strength in experimental models.
Patent Information
- Application Number
- PCT/JP2024/017061
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-05-09
- Filing Date
- 2024-05-08
- Publication Date
- 2024-11-14
AI Technical Summary
Current treatments for muscle atrophy lack effective inhibitors and understanding of the underlying mechanisms, making it difficult to suppress muscle atrophy caused by various factors such as aging, disuse, and steroid administration.
Development of pharmaceutical compositions that target Mkl1 and Mkl2 to increase their expression or stability, thereby suppressing the transcriptional activity of Foxo1, Foxo3, and Foxo4, which are involved in muscle atrophy, using substances like calpain inhibitors and viral vectors to deliver these agents to skeletal and cardiac muscles.
The increased expression or stability of Mkl1 and Mkl2 effectively suppresses muscle atrophy and enhances muscle strength, regardless of the underlying cause, as demonstrated by increased muscle weight and strength in experimental models.
Smart Images

Figure JP2024017061_14112024_PF_FP_ABST
Abstract
Description
Therapeutic agent for muscle atrophy and screening method
[0001] The present invention relates to a therapeutic agent for muscle atrophy and a muscle-building agent, and also to a method for screening these pharmaceutical compositions.
[0002] Muscle atrophy, or muscle loss, can occur for a variety of reasons. Known causes include myogenic muscle atrophy due to muscle disease, neurogenic muscle atrophy due to motor nerve damage, and disuse muscle atrophy due to reduced activity, such as prolonged bedriddenness. For example, sarcopenia refers to a condition in which muscle mass decreases with age. With the increase in the elderly population, the proportion of people diagnosed with primary sarcopenia, caused solely by aging, is increasing. Muscle mass generally begins to gradually decrease from around age 40. By age 70, compared to those in their 20s, skeletal muscle area is 25-30% lower and muscle strength is 30-40% lower, resulting in subjective symptoms such as difficulty lifting heavy loads. In addition to sarcopenia due to aging, sarcopenia can also occur secondary to nutritional deficiencies and illness. Furthermore, disuse atrophy due to muscle disuse, such as being bedridden, is also increasing with the increasing elderly population. Muscle atrophy is known to be caused by a variety of factors, including drugs such as steroids, endocrine disorders, cancer, wasting diseases such as hyperthyroidism and diseases accompanied by high fever, chronic kidney disease, chronic liver disease, chronic heart failure, and mental disorders such as depression. Muscle atrophy can result from a variety of causes, and the underlying mechanism is unclear. Therefore, the development of drugs to treat muscle diseases is desired.
[0003] Furthermore, in the livestock industry, increasing muscle mass leads to increased profits, so increasing muscle mass is an important issue along with meat quality. Currently, optimal fattening conditions for each animal species are being studied, including feeding methods and other feeding conditions. However, since there are various feeding conditions, it is difficult to establish optimal feeding conditions. In addition, attempts to increase muscle mass through genetic modification are being considered, but concerns about genetically modified animals mean that it is thought that this will be difficult to popularize to the general public.
[0004] The following reports have already been published regarding gene expression related to sarcopenia, muscle atrophy, or muscle mass enhancement. With aging, phenotypes of aging, such as a decrease in muscle cross-sectional area, are observed in the quadriceps femoris, but it has been reported that expression of the SRF, MRTF-A (Mkl1), and STARS genes is decreased, and expression of the RhoA and RhoGD1 genes is increased in the quadriceps femoris and triceps femoris (Non-Patent Document 1). While this document describes age-related muscle atrophy and the accompanying changes in gene expression, it does not clarify the details of the signal transduction system, and the genes controlling muscle atrophy remain unknown. Patent Document 1 also reports that comprehensive genetic analysis of skeletal muscle from immobilization muscle atrophy model mice and patients with immobilization muscle atrophy reveals that immobilization enhances the expression of the chemokine CXCL10, and that suppressing its expression may be able to suppress muscle atrophy.
[0005] Japanese Patent Application Laid-Open No. 2022-162858
[0006] Sakuma et al., Biochimica et Biophysica Acta,2008, Vol.1782,pp.453-461Milan, G. et al., Nature Communications, 2015, DOI: 10.1038 / ncomms7670Li, J., et al., Proc Natl Acad Sci USA,,2005. Vol.102(25): p. 8916-8921.Oh, J., et al., Proc Natl Acad Sci USA,2005. Vol.102(42): p. 15122-15127.
[0007] Although the above literature presents findings from genetic analysis of the genes that increase or decrease when muscle atrophy occurs, the mechanism of muscle atrophy onset has not been clarified. Therefore, it is not thought that muscle atrophy caused by various factors can be suppressed. Furthermore, no effective muscle atrophy inhibitors have been developed to date, and their development is desired.
[0008] The present inventors generated Mkl2 gene knockout mice and found a phenotype characterized by a significant reduction in white adipose tissue. Analysis of the mechanism of gene regulation by Mkl2 revealed that it suppresses the FoxO subfamily transcription factors Foxo1, Foxo3, and Foxo4. FoxO transcription factors are known to activate a group of muscle atrophy-causing genes (atrogenes) during various catabolic processes in skeletal muscle, inducing muscle atrophy. Analysis of the functions of Mkl1 and Mkl2 in skeletal muscle revealed that they regulate the expression of a group of muscle atrophy-causing genes, leading to the completion of the present invention.
[0009] The present invention relates to the following pharmaceutical compositions and screening methods: (1) A muscle atrophy inhibitor and / or muscle-enhancing agent, characterized in that the active ingredient is a substance that targets Mkl1 and / or Mkl2 and increases the amount of Mkl1 and / or Mkl2. The present inventors discovered that Mkl1 and Mkl2 regulate Foxo1, Foxo3, Foxo4, and the glucocorticoid receptor (GR), which are involved in the induction of the expression of genes that cause muscle atrophy, and thus completed the present invention.
[0010] (2) The muscle atrophy inhibitor and / or muscle-strengthening agent according to (1), wherein the active ingredient increases the amount of Mkl1 and / or Mkl2 in the nucleus. It has been discovered that Mkl1 / 2 directly binds to Foxo1 / 3 / 4. Therefore, by increasing the amount of Mkl1 / 2 in the nucleus, the transcriptional activity of Foxo1 / 3 / 4 can be suppressed, muscle atrophy can be suppressed, and muscle strengthening can be achieved.
[0011] (3) The muscle atrophy inhibitor and / or muscle-strengthening agent according to (1), characterized in that the muscle atrophy inhibitor is used to treat muscle atrophy caused by aging, disuse, neurogenic causes, malnutrition, or steroid administration. It has been found that increased expression of Mkl1 / 2 is effective against muscle atrophy caused by various causes. Therefore, regardless of the cause, the muscle atrophy inhibitor and muscle-strengthening agent can be expected to be effective in inhibiting muscle atrophy and strengthening muscles.
[0012] (4) The muscle atrophy inhibitor and / or muscle-enhancing agent according to (1), characterized in that Mkl1 and / or Mkl2 are introduced via a viral vector. Mkl1 was introduced into mice via an adeno-associated virus, and enhancement of skeletal and cardiac muscle was observed. Therefore, treatment using a viral vector is possible.
[0013] (5) The muscle atrophy inhibitor and / or muscle-enhancing agent according to (1), wherein the active ingredient increases the amount of Mkl1 and / or Mkl2 by inhibiting the degradation of Mkl1 and / or Mkl2. The degradation of Mkl1 / 2 was inhibited by MG-132 or the like, and stable expression was observed. Therefore, muscle atrophy can also be inhibited by inhibiting the degradation of Mkl1 / 2.
[0014] (6) The muscle atrophy inhibitor and / or muscle-building agent according to (5), wherein the active ingredient is a calpain inhibitor. Further investigations have revealed that calpain inhibitors inhibit the degradation of Mkl1 / 2 and stabilize the amount of Mkl1 / 2 in cells. Therefore, calpain inhibitors are thought to act as muscle atrophy inhibitors and muscle-building agents.
[0015] (7) The muscle atrophy inhibitor and / or muscle-enhancing agent according to any one of (1) to (6), wherein the muscle is skeletal muscle or cardiac muscle. In an experimental system using mice, an increase in the weight of skeletal muscle and cardiac muscle was observed.
[0016] (8) A method for screening for muscle atrophy inhibitors and / or muscle-enhancing agents, comprising exposing a candidate compound to cultured cells and using an increase in the amount of Mkl1 and / or Mkl2 in the cultured cells as an indicator. The present inventors have shown that the expression of muscle atrophy-causing genes regulated by the glucocorticoid receptor and Foxo1 / 3 / 4 transcription factors is controlled by Mkl1 / 2. Therefore, muscle atrophy inhibitors and muscle-enhancing agents can be screened using the expression of Mkl1 and Mkl2 as an indicator.
[0017] (9) The method for screening for muscle atrophy inhibitors and / or muscle-enhancing agents according to (8), wherein a reporter protein is fused to the Mkl1 and / or Mkl2 protein, and an increase in the reporter protein is used as an indicator. By using a system in which Mkl1 and Mkl2 expression is monitored by a reporter protein, high-throughput screening is also possible.
[0018] (10) A method for treating or preventing muscle atrophy, comprising administering the muscle atrophy inhibitor and / or muscle-enhancing agent according to any one of (1) to (7). (11) The method for treating muscle atrophy according to (10), which is for treating muscle atrophy caused by aging, disuse, neurogenic disease, fasting, steroid administration, or myocardial infarction.
[0019] Figure showing the results of microarray analysis of mRNA expression in white adipose tissue of wild-type mice and Mkl2 knockout mice. This figure shows genes with high mRNA expression in the white adipose tissue of Mkl2 knockout mice. This figure shows reduced skeletal muscle weight in Mkl2 knockout mice. This figure shows the results of analyzing Mkl1 and Mkl2 expression in the gastrocnemius muscle of C57BL / 6J mice after 4 weeks of forced treadmill exercise. This figure shows the results of Western blotting analysis of the intracellular localization of Mkl2 in the gastrocnemius muscle of C57BL / 6J mice immediately after forced treadmill exercise. This is a micrograph showing the results of analyzing the intracellular localization of Mkl1-eGFP and Mkl2-eGFP expressed in myotubes derived from C2C12 cells. This is a micrograph showing the translocation of Mkl2 from the cytoplasm to the nucleus upon myotube contraction due to electrical stimulation. The two photographs on the right are high-magnification images of the boxed areas in the photograph on the left.
[0033] Figure 1 shows the results of expression analysis of muscle atrophy-causing genes and Mkl1 and Mkl2 genes in the gastrocnemius muscles of young (8-week-old) and old (119-week-old) mice. Figure 2 shows the correlation between the expression levels of Mkl1 and Atrogin1, MuRF1, Foxo1, and Foxo3 in the gastrocnemius muscles of mice at each age. Figure 3 shows the results of analysis of changes in the expression of muscle atrophy-causing genes and Mkl1 and Mkl2 genes in the tibialis anterior muscle of mice that underwent sciatic nerve resection in the right hind limb. Figure 4 shows the results of analysis of changes in the expression of muscle atrophy-causing genes and their regulators (Foxo1 / 3 / 4) and Mkl1 and Mkl2 genes due to fasting. Figure 5 shows the results of analysis of the effect of Mkl1 and Mkl2 expression on the expression of muscle atrophy-causing genes and Foxo3 due to steroid addition to C2C12 cell-derived myotubes. Figure 1 shows the results of analyzing the effects of Mkl1 and Mkl2 on the transcriptional activity of the glucocorticoid receptor (GR) in a luciferase assay using a glucocorticoid receptor response element. Figure 2 shows the results of analyzing the effects of Mkl1 (upper panel) and Mkl2 (lower panel) on the transcriptional activity of Foxo1, Foxo3, and Foxo4 in a luciferase assay using a FoxO response element.Figure 1 shows the results of analyzing the effects of Mkl1 (top) and Mkl2 (bottom) on the transcriptional activity of Foxo1, Foxo3, and Foxo4 in the presence of the PI3K inhibitor LY294002 in luciferase assays with a FoxO response element in 293FT cells. Figure 2 shows the results of analyzing the expression of muscle atrophy-causing genes in C2C12 cell-derived myotubes after overexpression of Foxo1, Mkl1, and Mkl2. The left panel shows the results of analyzing mRNA expression, and the right panel shows the results of analyzing protein expression. Figure 3 shows the results of analyzing the expression of muscle atrophy-causing genes in C2C12 cell-derived myotubes after overexpression of Foxo3, Mkl1, and Mkl2. The left panel shows the results of analyzing mRNA expression, and the right panel shows the results of analyzing protein expression. This figure shows the results of analyzing the expression of genes that cause muscle atrophy in C2C12 cell-derived myotubes after adding the PI3K inhibitor LY294002 and the Mkl1 / 2 nuclear translocation inhibitor CCG-1423. The left shows the results of analyzing mRNA expression, and the right shows the results of analyzing protein expression. This figure shows the results of analyzing the expression of genes that cause muscle atrophy in C2C12 cell-derived myotubes after suppressing the expression of Mkl1 or Mkl2 using artificial microRNA (miRNA). The top left shows a schematic diagram of the structure of the designed miRNA. The top right shows the results confirming that the expression of Mkl1 and Mkl2 was suppressed by miRNA. The bottom shows the results of analyzing mRNA expression (left) and protein expression (right), demonstrating that suppression of Mkl1 and Mkl2 expression by miRNA resulted in increased expression of genes that cause muscle atrophy. Figure 1 shows the inhibitory effect of Mkl1 or Mkl2 on muscle atrophy when muscle atrophy is induced by expressing Foxo1 or Foxo3 in C2C12-derived myotubes. Figure 2 shows the results of analyzing the binding of Mkl1 and Mkl2 to Foxo1 by immunoprecipitation. Figure 3 shows the results of analyzing the binding of Mkl1 and Mkl2 to Foxo1 by split luciferase assay. Figure 4 shows the results of analyzing the binding of Mkl1 to Foxo3 and Foxo4, and the binding of Mkl2 to Foxo3 and Foxo4 by split luciferase assay. Figure 5 shows the results of analyzing the binding of Foxo1 to Mkl1 or Mkl2 in the presence of CCG-1423, an Mkl1 / 2 nuclear translocation inhibitor, by split luciferase assay.Figure 1 shows the results of analyzing the region required for the binding of Foxo1 and Mkl2 by constructing N-terminal deletion mutants. Figure 2 shows that the transcription activation domain (TAD) of Mkl2 acts on the full-length Foxo1 protein (left) and the Foxo1 protein DNA-binding domain (Forkhead domain) to suppress transcriptional activity. Figure 3 shows the results of analyzing, by chromatin immunoprecipitation (ChIP) assay, changes in Foxo3 binding to the genomic region surrounding the muscle atrophy-causing gene upon expression of Mkl1 or Mkl2. Figure 4 shows the results of analyzing the time-dependent changes in Akaluc expression in mice systemically administered with adeno-associated virus (MyoAAV.2A Mhck7-Akaluc). Figure 5 shows the expression of eGFP in each muscle and heart in mice systemically administered with adeno-associated virus (MyoAAV.2A Mhck7-eGFP). Figure 1 shows the results of comparative analysis of the induction of Foxo1 / 3 / 4 expression under fasting conditions after expressing Mkl1 in the muscles of C57BL / 6J mice using an adeno-associated virus. Figure 2 shows the results of analysis of the expression of muscle atrophy-causing genes and Foxo1 / 3 / 4 after Mkl1 was introduced into the muscles of C57BL / 6J mice using an adeno-associated virus and dexamethasone sodium phosphate was administered intraperitoneally. Figure 3 shows the results of analysis of gastrocnemius muscle weight after systemic administration of an adeno-associated virus (MyoAAV.2A Mhck7-Mkl1) to mice. Figure 4 shows the results of analysis of heart weight after systemic administration of an adeno-associated virus (MyoAAV.2A Mhck7-Mkl1) to mice. Figure showing the results of analyzing the half-life by expressing Mkl1 and Mkl2 using the Tet-On promoter and removing the expression inducer doxycycline. Figure showing the results of analyzing the stability of Mkl1 and Mkl2 proteins using MG-132. Figure showing the results of analyzing the stability of Mkl1 and Mkl2 proteins using a ubiquitin proteasome inhibitor and a calpain inhibitor. Schematic diagram showing the points of action of Mkl1 and Mkl2 in muscle atrophy and muscle mass enhancement.
[0020] As used herein, the term "muscle atrophy therapeutic agent" or "muscle-enhancing agent" refers to any agent capable of increasing the amount of Mkl1 or Mkl2 in muscle. For example, the agent may enhance Mkl1 or Mkl2 expression, or may inhibit its degradation, thereby increasing its intracellular amount. The agent may also include any type of substance. Specifically, the agent may include low-molecular-weight compounds, nucleic acid drugs, peptide or protein preparations, and biological preparations introduced into the body via viral vectors such as adenovirus vectors and adeno-associated virus vectors. Furthermore, since livestock are fattened for meat production, muscle-enhancing agents administered to livestock are preferably extracted from natural materials such as plants.
[0021] The method of administration of the pharmaceutical composition of the present invention to patients or animals can be determined appropriately depending on the type of active ingredient, and may be either oral or parenteral. For oral administration, preferred dosage forms include solids (including tablets, capsules, drops, and lozenges), granules, powders, powders, and liquids (including oral solutions, emulsions, and syrups). For solids, they can be coated as needed in dosage forms known in the art, such as sugar-coated tablets, gelatin-encapsulated tablets, enteric-coated tablets, film-coated tablets, double tablets, and multi-layer tablets. For administration to livestock, they may be in a form that can be mixed with feed.
[0022] For parenteral administration, subcutaneous, intramuscular, intravenous, intraperitoneal, or intranasal administration is useful. In a preferred embodiment, administration is by subcutaneous or intramuscular injection. In another preferred embodiment, administration is by intravenous drip or intravenous injection. The pharmaceutical composition may also contain a pharmaceutically acceptable carrier. Specific pharmaceutically acceptable carriers include all physiologically acceptable solvents, dispersion media, antibacterial or antifungal agents, isotonic agents, and absorption delaying agents. Examples of pharmaceutically acceptable carriers include water, saline, phosphate-buffered saline, dextrose, glycerin, ethanol, and the like, and the composition may contain at least one or more of these carriers. The pharmaceutically acceptable carrier may further contain small amounts of substances that enhance efficacy, such as wetting agents, emulsifiers, preservatives, and buffers. It is desirable to continue treatment for an appropriate period of time while monitoring the therapeutic effect.
[0023] The pharmaceutical composition of the present invention can also be administered continuously from the viewpoint of preventing muscle atrophy, such as preventing sarcopenia or preventing disease. The dosage may be lower than that for therapeutic purposes. From the viewpoint of preventing disease or preventing disease, it is not necessary to actively increase Mkl1 and Mkl2, and a suppression of decreased expression may be sufficient. Furthermore, instead of a pharmaceutical composition, the composition may be continuously ingested in the form of a supplement or nutritional supplement.
[0024] Muscle atrophy is known to occur due to the activation of multiple genes known as the muscle atrophy gene cluster. Furthermore, the expression of these genes is induced by the nuclear receptor glucocorticoid receptor (GR) and the transcription factors Foxo1, Foxo3, and Foxo4. It has been reported that mice lacking Foxo1 / 3 / 4 in muscle exhibit resistance to muscle atrophy (Non-Patent Document 2). FoxO proteins are transcription factors belonging to the Forkhead transcription factor family, and four isoforms, Foxo1, Foxo3, Foxo4, and Foxo6, are known to exist in mammals. The present inventors generated Mkl2 knockout mice and analyzed their phenotypes, revealing a significant reduction in white adipose tissue. Furthermore, in the course of analyzing the molecular mechanism, we discovered that Mkl1 and Mkl2 suppress the transcriptional activation ability of the transcription factors Foxo1, Foxo3, and Foxo4, and further suppress the transcriptional activation ability of the glucocorticoid receptor, which is responsible for inducing Foxo expression, thereby suppressing the expression of a group of genes that cause muscle atrophy, and thus completed the present invention (see Figure 13).
[0025] The following data are presented for further explanation. Unless otherwise noted, the following analyses were performed using techniques commonly employed in this field. Mkl2 is known to be a coactivator of the transcription factor Srf. However, Mkl2 knockout mice (hereinafter referred to as Mkl2 KO mice, or simply Mkl2 KO) have been reported to be embryonic lethal due to developmental abnormalities in the cardiovascular system, such as hypoplasia of the sixth pharyngeal arch artery and ventricular septal defects (Non-Patent Documents 3 and 4). Therefore, the function of Mkl2 from late development to adulthood was unknown. The present inventors discovered that heterosis in crossing an ICR background with a C57BL / 6N background avoided embryonic lethality and allowed the generation of Mkl2 KO mice.
[0026] Specifically, Mkl2 KO mice were generated as follows. ES cells (MrtfbTM1a(KOMP)Mbp) were purchased and isolated from the Knockout Mouse Project (KOMP). MrtfbTM1a(KOMP)Mbp mice were subsequently crossed with CAG-FRT mice and CAG-Cre mice to generate heterozygous mice lacking exons 11 and 12 of Mkl2. These heterozygous mice were maintained in C57BL / 6N and ICR mouse strains, and Mkl2 KO mice lacking both alleles were generated due to hybrid vigor between the two strains.
[0027] Although the role of Mkl1, a paralog of Mkl2, in adipogenesis has already been reported, its function remains unclear. While some reports suggest that Mkl1 negatively regulates white adipocyte differentiation, conflicting reports suggest that Mkl1 induces mesenchymal stem cells to differentiate into white adipocytes but not brown adipocytes. To investigate the mechanism of white adipose tissue loss in Mkl2 KO mice and the effects of Mkl2 deficiency on various transcription factors, we extracted RNA from the inguinal white adipose tissue of Mkl2 KO mice and their littermates and analyzed its expression (Figure 1).
[0028] RNA extracted from adipose tissue was analyzed for expression by microarray analysis (Figure 1A). Mkl2 KO mice and their wild-type littermates were euthanized, and white adipose tissue was isolated from the groin. TRIzol Reagent (Thermo Fisher Scientific) was added, and the tissue was disrupted using a Micro Smash MS-100R. RNA purification was performed according to the reagent's instructions. The purified RNA was subjected to microarray analysis using 3D-Gene (TORAY). Genes with differential expression between wild-type and Mkl2 KO mice were extracted. Genes with altered expression in Mkl2 KO mice were extracted (Figure 1B), and upstream regulatory genes that could explain these altered gene expression were further analyzed using Ingenuity™ Pathway Analysis (IPA). We predicted changes in the activation / inactivation state of transcription factors in the white adipose tissue of Mkl2 KO mice and extracted the top 10 transcription factors located upstream of RNAs whose expression was altered by microarray analysis (Table 1).
[0029]
[0030] IPA analysis predicted that the transcriptional activity of the transcription factor Srf, which is known to interact with Mkl2 and function as a coactivator, was suppressed. Furthermore, Foxo1 was predicted to be activated, ranking higher than Srf. The inventors analyzed the phenotype of reduced white adipose tissue in Mkl2 KO mice and found that Mkl1 and Mkl2 suppress the transcription factor Foxo1. As mentioned above, Foxo1 / 3 / 4 transcription factors are known to activate muscle atrophy-causing genes and induce muscle atrophy during various catabolic processes in skeletal muscle. Therefore, we analyzed the involvement of Mkl2 and its paralog, Mkl1, in muscle atrophy.
[0031] First, we measured whether skeletal muscle weight was reduced in Mkl2 KO mice (Figure 2). We isolated the gastrocnemius (Gast), soleus (Soleus), plantaris (Plantarsus), tibialis anterior (TA), and extensor digitorum longus (EDL) muscles from 22-week-old Mkl2 KO mice, wild-type (WT), and heterozygous (Ht) mice, and measured their muscle weights. All muscle weights were significantly reduced in Mkl2 KO mice compared to wild-type and heterozygous mice. Therefore, it was clear that Mkl2 KO significantly reduced skeletal muscle weight. In this specification, * indicates P<0.05, and ** indicates P<0.01.
[0032] Therefore, we analyzed the behavior of Mkl1 and Mkl2 in muscle tissue. Ten-week-old C57BL / 6J mice were forced to run on a treadmill for 60 minutes per day for four weeks. The treadmill speed was increased by 1 m / min every 10 minutes until it reached 20 m / min. After four weeks of forced exercise, the expression of Mkl1 and Mkl2 in the gastrocnemius muscle was analyzed by RT-qPCR (n = 3). Expression of Mkl1 and Mkl2 was found to be approximately 2.5-fold higher in the exercise group (Exc; Exercise) than in the sedentary group (Sed; Sedentary) (Figure 3A). Furthermore, the intracellular localization of Mkl2 protein in the gastrocnemius muscle of mice from the treadmill exercise and sedentary groups was analyzed by Western blotting. Immediately after 3 hours of treadmill exercise, the cytoplasm and nuclei of gastrocnemius muscles were fractionated using the Subcellular Protein Fractionation Kit for Tissues (Thermo Fisher Scientific) and analyzed by Western blotting. MKL2 / MRTF-B antibody (Cell Signaling Technology) was used as the primary antibody, and HRP-labeled anti-rabbit IgG (Cell Signaling Technology) was used as the secondary antibody. Measurements were performed using chemiluminescence (Chemi-Lumi One Super, Nacalai Tesque). Comparing the amounts of Mkl2 protein between the exercise and non-exercise groups, we found that the amount of Mkl2 in the cytoplasmic fraction did not change between the exercise and non-exercise groups, but the amount of Mkl2 in the nuclear fraction increased significantly after exercise. It was revealed that Mkl2 translocates to the nucleus following exercise (Figure 3B). Lmna and Gapdh are proteins present in the nucleus and cytoplasm, respectively.
[0033] Fusion proteins of Mkl1 or Mkl2 with eGFP were incorporated into a Tet-On inducible expression system, then incorporated into an adenoviral vector to generate Tet-On adenovirus, which was then expressed in myotubes. Myotubes were produced by culturing C2C12 cells (ATCC) in DMEM (Nacalai Tesque) containing 10% FBS (Gibco) on dishes coated with Geltrex™ LDEV-Free Reduced Growth Factor Basement Membrane Matrix (Thermo Fisher Scientific). After C2C12 cells reached confluence, the medium was replaced with DMEM (Nacalai Tesque) containing 2% Horse Serum (Gibco), and differentiation induction was initiated. On day 3 of differentiation induction, adenovirus was added to the culture medium for infection, and the next day, doxycycline (Wako) was added to express Mkl1-eGFP and Mkl2-eGFP (Fig. 3C). It was revealed that Mkl1 is localized in the nucleus, and Mkl2 in the cytoplasm in myotubes.
[0034] Myotubes expressing Mkl2-eGFP using Tet-On adenovirus were subjected to electrical pulse stimulation (EPS) using an electrical stimulator, causing rhythmic contraction in the myotube cells (Figure 3D). Upon electrical stimulation (EPS in the figure), Mkl2 translocates from the cytoplasm to the nucleus. It is thought that myotube contraction due to electrical stimulation, i.e., muscle contraction associated with exercise, causes Mkl2 to translocate to the nucleus, increasing muscle mass and suppressing muscle atrophy.
[0035] Muscle mass varies under various conditions. Aging, along with exercise, is a factor involved in the increase or decrease of muscle mass. First, RT-qPCR was used to analyze the expression of age-related muscle atrophy-causing genes, as well as Mkl1 and Mkl2. Expression of Atrogin-1, MuRF1, Mkl1, and Mkl2 was analyzed in the gastrocnemius muscles of young (8-week-old) and old (119-week-old) C57BL / 6J mice. Atrogin-1 and MuRF1 are known to be genes associated with muscle atrophy (a group of genes responsible for muscle atrophy) and are ubiquitin ligases specific to skeletal and cardiac muscles. Increased expression of Atrogin-1 and MuRF1 was observed in old (119-week-old) mice compared with young (8-week-old) mice. Meanwhile, a significant decrease in Mkl1 expression was observed (Figure 4A). These results suggest that the expression of Mkl1 decreases with age and is negatively correlated with the expression of genes that cause muscle atrophy. The decrease in expression level of Mkl1 with age was more pronounced than that of Mkl2.
[0036] We analyzed the correlation between the expression levels of Mkl1 and Atrogin1, MuRF1, Foxo1, and Foxo3 in the gastrocnemius muscles of mice at various ages (Figure 4B). The horizontal axis represents the expression level of Mkl1, and the vertical axis represents the expression levels of Atrogin1, MuRF1, Foxo1, or Foxo3, respectively. RNA-seq data (GEO accession no. GSE145480) registered in the public database Gene Expression Omnibus was reanalyzed. For reanalysis, each expression level was normalized using DESeq. A strong inverse correlation was observed between Mkl1 and a group of genes responsible for muscle atrophy (Atrogin1 and MuRF1). Furthermore, an even stronger inverse correlation was observed between the expression levels of Mkl1 and Foxo1 and Foxo3, suggesting that Mkl1 may also suppress the transcriptional activity of the glucocorticoid receptor (GR), a nuclear receptor that controls the expression of Foxo1 and Foxo3.
[0037] Next, using a muscle atrophy model induced by sciatic nerve resection, we analyzed the expression of Atrogin-1, MuRF1, Mkl1, and Mkl2 by RT-qPCR. The sciatic nerves of the right hind limbs of 10-week-old C57BL / 6J mice were resected. The time before resection was designated Day 0, and on Days 3 and 7 after resection, the left and right tibialis anterior muscles were sampled to analyze changes in the expression of the muscle atrophy-causing genes, Mkl1 and Mkl2, in the tibialis anterior muscle. On Day 0, no differences in gene expression were observed between the left and right sides. However, on Days 3 and 7 after resection, increased expression of Atrogin-1 and MuRF1 was observed in the right tibialis anterior muscle (the resected side), and decreased expression of Mkl1 was observed. Contrary to Mkl1, increased expression of Mkl2 was observed (Figure 5).
[0038] Furthermore, because muscle atrophy can also occur in poor nutritional status, we analyzed the changes in expression of fasting-induced muscle atrophy-causing genes and their regulatory factors. Nine-week-old C57BL / 6J male mice were fasted for 24 hours, and then euthanized and their gastrocnemius muscles were sampled. Changes in the expression of muscle atrophy-causing genes, Foxo1 / 3 / 4, and Mkl1 / 2, in the gastrocnemius muscles were analyzed in the same manner. Fasted mice (Fast) showed significantly increased expression of muscle atrophy-causing genes, Atrogin-1 and MuRF1, compared with mice maintained on a normal diet (Fed). Furthermore, Foxo1 and Foxo3, which regulate muscle atrophy-causing genes, also showed significant increases in the fasted group, and a trend toward increased expression of Foxo4 was also observed. On the other hand, expression of Mkl1 and Mkl2 was suppressed in the fasting group, and particularly, expression of Mkl1 was significantly suppressed (FIG. 6).
[0039] It has long been known that steroid treatment, such as dexamethasone, can cause muscle atrophy. When muscle atrophy-causing genes are induced, Mkl1 or Mkl2 was expressed using a Tet-On adenovirus vector, and we analyzed whether steroid-induced changes in the expression of the muscle atrophy-causing genes, FoxO, were observed. Specifically, C2C12 cells were induced to differentiate, and on day 3, they were infected with Tet-On adenoviruses incorporating Mkl1 or Mkl2. On day 4, gene expression was induced by the addition of doxycycline, and 10 μM hydrocortisone or 10 μM dexamethasone was also added (Figure 7A). The results demonstrated that the expression of Atrogin-1, MuRF1, and Foxo3 genes was enhanced by hydrocortisone and dexamethasone, and suppressed by the expression of Mkl1 or Mkl2.
[0040] It is known that glucocorticoid receptor (GR)-mediated induction of Foxo gene expression during muscle atrophy is mediated by the glucocorticoid receptor (GR). To determine whether the suppression of Foxo gene expression by Mkl1 during muscle atrophy is due to glucocorticoid receptor suppression, we used a luciferase assay (Figure 7B). A luciferase reporter was constructed by incorporating a sequence (SEQ ID NO: 1) containing four glucocorticoid receptor response elements (GR-REs) into the pGL4.23 plasmid (Promega) and used for the analysis. Luciferase activity was induced by glucocorticoid receptor (GR) expression but suppressed by Mkl1 and Mkl2 expression. Furthermore, the suppressive effect of Mkl1 and Mkl2 was observed even when glucocorticoid receptor (GR) activation was induced in the presence of dexamethasone. Therefore, it is thought that Mkl1 and Mkl2 suppress muscle atrophy caused by fasting or steroids by suppressing the transcriptional activity of the glucocorticoid receptor. These results suggest that Mkl1 and Mkl2 also regulate the glucocorticoid receptor.
[0041] Furthermore, as shown by the in vivo experimental data below, Mkl1 expression induces cardiac hypertrophy, suggesting that it can induce cardiomyocyte hypertrophy via glucocorticoid receptor regulation as well as cell division promotion. Therefore, induction of Mk11 / 2 expression is thought to be applicable to regenerative medicine, such as myocardial regeneration after myocardial infarction.
[0042] As shown above, in muscle atrophy caused by various factors such as aging, disuse, neurogenic disease, fasting, and steroid administration, the expression of Mkl1 is inversely correlated with the expression of genes that cause muscle atrophy. Furthermore, it has been revealed that Mkl1 and Mkl2 regulate genes that cause muscle atrophy through the suppression of glucocorticoid receptors and Foxo1 / 3 / 4. Furthermore, since Mkl1 / 2 levels increase with exercise, it is thought that Mkl1 / 2 regulate muscle strengthening and the suppression of muscle atrophy (see Figure 13).
[0043] Mkl1 and Mkl2 regulate muscle atrophy-causing genes via Foxo1 / 3 / 4 and the glucocorticoid receptor (GR). However, Mkl1 and Mkl2 differ in their behavior and response to aging, sciatic nerve resection, fasting, and steroid administration. Furthermore, Mkl1 and Mkl2 also differ in their intracellular localization; Mkl2 resides in the cytoplasm and translocates to the nucleus upon exercise, whereas Mkl1 localizes to the nucleus. These results suggest that Mkl1 and Mkl2 play similar roles in regulating muscle atrophy-causing genes, but are differentially regulated and act on muscle atrophy due to different causes. Although further analysis is needed, pharmaceutical compositions that increase Mkl2, which translocates to the nucleus and exerts its function upon exercise, are likely suitable for use as pharmaceutical compositions or supplements administered at pre-disease stages to enhance the effectiveness of rehabilitation or prevent sarcopenia. Furthermore, since Mkl1, which is localized in the cell nucleus, is thought to act more directly on muscle atrophy, it may be effective against more severe muscle atrophy. Therefore, it is preferable to develop therapeutic drugs for muscle atrophy, or preventive drugs and supplements for preventing muscle atrophy, taking into account the characteristics of Mkl1 and Mkl2.
[0044] Since Mkl1 / 2 are thought to regulate muscle growth and atrophy through FoxO inhibition, we analyzed this regulatory mechanism. A luciferase reporter construct containing a FoxO-responsive element (SEQ ID NO: 2) consisting of a repeat of the Foxo1-binding motif TGTTTAC was constructed, and the effects of Mkl1 and Mkl2 on the transcriptional activity of Foxo1 / 3 / 4 were analyzed. 293FT cells (Thermo Fisher Scientific) were transfected with the luciferase reporter construct and each gene using Polyethyleneimine Max (MW 40,000) (Polysciences). Luciferase activity was measured as follows. Cells were harvested 48 hours after transfection, and a luminescent substrate was added to the cell extract. Luminescence was measured using a GloMax™ Discover Microplate Reader. Expression of either Foxo1, Foxo3, or Foxo4 significantly reduced transcriptional activity when Mkl1 (Fig. 8A, upper panel) or Mkl2 (Fig. 8A, lower panel) was expressed.
[0045] Furthermore, because Foxo proteins are known to be inactivated by the PI3K / Akt pathway, we activated Foxo1, Foxo3, and Foxo4 in the presence of LY294002 (Fujifilm Wako Pure Chemical Industries, Ltd.), a PI3K / Akt pathway inhibitor, and analyzed their activity by luciferase assay (Figure 8B). LY294002 enhanced the transcriptional activity of Foxo1, Foxo3, and Foxo4, but expression of Mkl1 or Mkl2 suppressed their activation.
[0046] Furthermore, C2C12 cells were differentiated into myotubes, and Foxo1 or Foxo3 and Mkl1 or Mkl2 were overexpressed by adenoviral vector transduction. The mRNA expression of muscle atrophy-causing genes was analyzed by RT-qPCR (Figures 8C and 8D, left). Protein expression was also analyzed by Western blotting (Figures 8C and 8D, right). Four days after induction of myotube differentiation, 20 μM of the PI3K inhibitor LY294002 (Fujifilm Wako Pure Chemical Corporation) was added to the culture medium, and analysis was performed after 24 hours of treatment. Akt phosphorylates Foxo1 / 3 / 4, inhibiting their nuclear translocation and suppressing their activity. Addition of the PI3K inhibitor LY294002 inhibits Foxo1 / 3 / 4 phosphorylation, leading to their nuclear accumulation and maximal enhancement of their activity.
[0047] Both Mkl1 and Mkl2 suppressed the expression of Atrogin-1 and MuRF1, both of which are causative genes for muscle atrophy, when Foxo1 was introduced and Mkl1 or Mkl2 was expressed (Fig. 8C) and when Foxo3 was introduced and Mkl1 or Mkl2 was expressed (Fig. 8D). Furthermore, the suppressive effects of Mkl1 and Mkl2 were observed even in the presence of the PI3K inhibitor LY294002, demonstrating that FoxO suppresses gene expression regardless of whether the PI3K / Akt pathway is inhibited.
[0048] C2C12 cells were induced to differentiate, and on day 4 of differentiation, myotubes were treated with 20 μM PI3K inhibitor LY294002 and 10 μM Mkl1 / 2 nuclear translocation inhibitor CCG-1423 (Cayman Chemical) for 24 hours. Expression of muscle atrophy-causing genes was analyzed by RT-qPCR (Figure 8E, left) or Western blotting (Figure 8E, right). As described above, addition of LY294002 activates the FoxO gene cluster, and addition of CCG-1423 inhibits nuclear translocation of Mkl1 and Mkl2. Therefore, FoxO gene activity is maximally enhanced. Expression of Atrogin-1 or MuRF1, which are muscle atrophy-causing genes, was enhanced by LY294002 and CCG-1423 treatment. Furthermore, additive effects were observed when both were added simultaneously.
[0049] Next, we used artificial microRNAs (miRNAs) to suppress Mkl1 and Mkl2 expression and analyzed the expression of genes responsible for muscle atrophy (Figure 8F). We constructed an adenoviral vector containing three tandem hairpin miRNAs whose expression was controlled by Tet-ON (Figure 8F, top left). The following sequences were used for miRNA expression: Mkl1#1: SEQ ID NO: 3, Mkl1#2: SEQ ID NO: 4, Mkl2#1: SEQ ID NO: 5, Mkl2#2: SEQ ID NO: 6. Expression of the respective Mkl1 and Mkl2 miRNAs specifically suppressed Mkl1 or Mkl2 expression (Figure 8F, top right). Furthermore, RT-qPCR (Figure 8F, bottom left) and Western blotting (Figure 8F, bottom right) showed that when miRNAs were used to suppress the expression of either Mkl1 or Mkl2, the expression of Atrogin-1 or MuRF1, which are genes that cause muscle atrophy, was increased. These analytical results revealed that the expression of Mkl1 and Mkl2 suppresses FoxO transcriptional activity and suppresses the expression of genes that cause muscle atrophy.
[0050] In addition, myotubes were formed in C2C12 cells by differentiation induction, and a Foxo1 / eGFP fusion protein (Foxo1-eGFP), Mkl1, or Mkl2 was introduced via adenovirus, and the effects were analyzed (Figure 8G, top panel). Introduction of Foxo1-eGFP induced myotube atrophy, but simultaneous expression of Mkl1 or Mkl2 maintained myotubes and demonstrated an inhibitory effect on muscle atrophy. Foxo3 and GFP were also introduced separately via adenovirus, and the effects of Mkl1 or Mkl2 were analyzed (Figure 8G, bottom panel). Mkl1 and Mkl2 were also shown to have an inhibitory effect on muscle atrophy in response to Foxo3 expression. Note that eGFP was used to visualize myotubes.
[0051] Next, we examined whether the repression of Foxo1 by Mkl1 and Mkl2 was due to direct binding using immunoprecipitation (Fig. 9A) and split luciferase assays (Figs. 9B and 9C). N-terminal Flag-tagged Foxo1 and C-terminal HA-tagged Mkl1 (Fig. 9A, upper left), N-terminal Flag-tagged Mkl1 and N-terminal HA-tagged Foxo1 (Fig. 9A, upper right), N-terminal Flag-tagged Foxo1 and N-terminal HA-tagged Mkl2 (Fig. 9A, lower left), N-terminal Flag-tagged Mkl2 and N-terminal HA-tagged Foxo1 were prepared and mixed in each combination. 293FT cells were transfected with Lipofectamine™ 3000 Transfection Reagent (Thermo Fisher Scientific) for expression. Two days later, cells were harvested and immunoprecipitated with anti-FLAG antibody to analyze whether co-precipitation occurred. All combinations of Foxo1 and Mkl1 / Mkl2 co-precipitated with anti-FLAG antibody, indicating direct binding of Foxo1 to Mkl1 and Mkl2.
[0052] Next, protein-protein interaction (PPI) between Foxo1 and Mkl1 or Mkl2 was analyzed using a split luciferase assay (NanoBiT™ PPI Starter Systems, Promega) (Figure 9B). Plasmids bearing an N-terminal LgBiT tag, a C-terminal LgBiT tag, an N-terminal SmBiT tag, and a C-terminal SmBiT tag were constructed for Foxo1, Mkl1, and Mkl2, respectively, and the interaction between each protein was analyzed. The SmBiT tag is indicated as Sm in Figure 9B. 293FT cells were seeded in a 96-well white microplate and co-transfected the following day with a plasmid bearing an LgBiT tag and a plasmid bearing an SmBiT tag. To measure background signals, we used SmBiT-tagged HaloTag plasmid (Sm-HT) instead of SmBiT-tagged Foxo1, Mkl1, or Mkl2. Twenty-four hours after transfection, a luminescent substrate was added and luminescence was measured. Significant signals were detected with the combination of Foxo1 and Mkl1 or Mkl2, regardless of whether the NanoBiT-tagged construct was attached to the N- or C-terminus.
[0053] We also analyzed the protein interaction between Foxo3 or Foxo4 and Mkl1 or Mkl2 (Figure 9C). Here, we show an example in which LgBiT tags were added to Mkl1 and Mkl2, and SmBiT tags were added to Foxo3 and Foxo4, and then analyzed the protein-protein interaction. The combination of Mkl1 or Mkl2 with Foxo3 or Foxo4 resulted in detectable signal levels above background levels. The detection of significant signals in the combination of Foxo1 / 3 / 4 with Mkl1 or Mkl2 indicates direct binding of Foxo1 / 3 / 4 to Mkl1 or Mkl2. Specifically, split luciferase assays also demonstrated that Mkl1 and Mkl2 directly bind to Foxo1 / 3 / 4.
[0054] Using a system in which nuclear translocation of Mkl1 and Mkl2 was inhibited in the presence of CCG-1423, we analyzed whether changes in the binding of Foxo1 to Mkl1 and Mkl2 occurred (Figure 9D). Analysis was performed using a combination of LgBiT-tagged Foxo1 and SmBiT-tagged Mkl1 (Figure 9D, top panel) or Mkl2 (Figure 9D, bottom panel). When nuclear translocation of Mkl1 and Mkl2 was inhibited by CCG-1423, a decrease in signal intensity was observed, indicating a significant decrease in the binding of Foxo1 to Mkl1 and Mkl2. This suggests that Mkl1 and Mkl2 directly bind to Foxo1 in the nucleus and suppress its transcriptional activity.
[0055] To determine which regions of Foxo1 and Mkl2 are required for their binding, we constructed N-terminal deletion mutants and analyzed them by split luciferase assay. Deletion mutants of Foxo1 (Fig. 10A, top panel) and Mkl2 (Fig. 10A, bottom panel) were constructed and analyzed. Foxo1 lacking the forkhead domain exhibited significantly reduced binding to Mkl2 (Fig. 10A, top panel). The forkhead domain is the DNA-binding domain of Foxo1 and is required for Foxo1 to directly bind to cis-regulatory elements present in gene promoters and enhancers. The result that the Forkhead domain is required for the binding of Mkl2 to Foxo1 suggests that Mkl2 inhibits the DNA-binding ability of Foxo1 by binding to the DNA-binding domain of Foxo1, thereby suppressing the transcriptional activity of Foxo1.
[0056] On the other hand, split luciferase assays using a series of deletion mutants of Mkl2 demonstrated that the Mkl2 transcription activation domain (TAD) alone reduced the signal more slowly than the full-length Mkl2, demonstrating that the TAD domain binds to Foxo1 (Fig. 10A, bottom). Furthermore, the Mkl2 TAD domain alone significantly suppressed Foxo1 transcriptional activity (Fig. 10B, left). Furthermore, the TAD domain also exhibited an inhibitory effect on the fusion protein of Foxo1 forkhead domain and VP16 (Fig. 10B, right). This suggests that the TAD domains of Mkl1 and Mkl2 bind to the Foxo1 DNA-binding domain and suppress Foxo1 transcriptional activity. Normally, the TAD domain is responsible for transcriptional activation, but a new mode of inhibition was revealed in which it inhibits and suppresses Foxo1 DNA binding by binding to the DNA-binding domain of Foxo1.
[0057] C2C12 cells were induced to differentiate into myotubes, and in the presence of Mkl1 or Mkl2, Foxo3 binding to the genomic region surrounding the muscle atrophy-causing gene cluster was analyzed by chromatin immunoprecipitation (ChIP) assay. HA-tagged Foxo3 (Foxo3-HA), Mkl1, or Mkl2 was expressed in myotubes differentiated from C2C12 cells using adenovirus. The PI3K inhibitor LY294002 was added at 20 μM to induce Foxo3 nuclear translocation. Myotubes were then fixed with 1% formalin, and chromatin was extracted using lysis buffer and sheared by sonication. Chromatin immunoprecipitation (ChIP) was performed using HA tag antibody (Proteintech) or control antibody conjugated to Dynabeads™ Protein A (Thermo Fisher Scientific). After washing with RIPA buffer, the samples were heated to 65°C to reverse cross-linking. After RNase A and Proteinase K treatment, the samples were purified by phenol-chloroform extraction and ethanol precipitation. The enrichment rate of the purified genomic DNA was analyzed by qPCR using a primer set that detects Foxo3 binding sites around the muscle atrophy-causing gene cluster. Foxo3 binding sites around the Atrogin-1 and MuRF1 genes were quantified by qPCR (Figure 10C). The binding of Foxo3 to Atrogin-1 or MuRF was significantly reduced when Mkl1 or Mkl2 was exogenously expressed. Thus, ChIP assays also demonstrated that direct binding of Mkl1 or Mkl2 to FoxO proteins inhibits their activity.
[0058] These results suggest that increased expression of Mkl1 / 2 protein inhibits the transcription factor function of FoxO protein by binding to FoxO protein, inhibiting the induction of muscle atrophy-causing genes. This suggests that Mkl1 / 2 protein acts as an inhibitor of muscle atrophy. In other words, enhancing Mkl1 / 2 expression can inhibit muscle atrophy or strengthen muscles. Because Mkl1 / 2 is located upstream of FoxO, controlling it as a molecular target is thought to enable more sensitive inhibition of muscle atrophy.
[0059] Using an in vivo mouse system, we analyzed whether enhancing Mkl1 / 2 expression inhibits muscle atrophy or enhances muscle growth. Muscle-specific adeno-associated viruses were produced using the AAV-MAX Helper-Free AAV Production System Kit (Thermo Fisher Scientific). VPC2.0 cells were transfected with a helper plasmid, Rep / Cap plasmid, and a transfer plasmid, and 72 hours later, AAV was extracted using citrate buffer (55 mM citric acid, 55 mM sodium citrate, 800 mM NaCl). After neutralization with HEPES (pH 8.0), PEG precipitation was performed. After resuspension, the AAV was treated with Benzonase and purified by density gradient centrifugation using Optiprep. The purified AAV was then administered to mice via tail vein injection after buffer replacement with PBS.
[0060] The Transfer plasmid was constructed by removing all sequences between the ITRs of the pAAV-CMV Vector (TaKaRa) and incorporating the Mhck7 promoter, a hybrid promoter consisting of the mouse muscle creatine kinase gene promoter and the mouse α-myosin heavy chain gene promoter, and the SV40 polyA transcription termination signal. Furthermore, eGFP, Akaluc, or Mkl1 sequences were incorporated into the Transfer plasmid. The DNA templates for the Mhck7 promoter, Akaluc, and Mkl1 were constructed by artificial gene synthesis (Integrated DNA Technologies). Akaluc and Mkl1 were codon-optimized. The Rep / Cap plasmid encoding MyoAAV.2A was constructed using pUCmini-iCAP-PHP. This plasmid was created by substituting the sequence SAQQAVRTSL (SEQ ID NO: 7) of hypervariable region VIII with GPGRGDQTTL (SEQ ID NO: 8) by inverse PCR based on S (Addgene). pHelper (TaKaRa) was used as the helper plasmid. In the following experiments, when genes such as eGFP and Akaluc were introduced using adeno-associated virus, the plasmids were constructed with the same structure except for the respective gene sequences.
[0061] First, we investigated whether a muscle-tropic adeno-associated virus (AAV) could be used to introduce a foreign gene into mouse muscle using Akaluc or eGFP. 11 MyoAAV.2A Mhck7-Akaluc (vg) was administered, and Akaluc expression was measured over time by IVIS (Figure 11A). In mice administered the virus, expression was observed on day 4, and Akaluc expression increased over time, with systemic expression observed from day 7 onwards and strong expression observed from day 14 onwards. Furthermore, strong expression was observed to be specifically induced in muscle and heart.
[0062] In addition, MyoAAV.2A Mhck7-eGFP was administered, and 38 days after administration, the gastrocnemius muscle, tibialis anterior muscle, plantaris muscle, extensor digitorum longus muscle, and heart were removed and analyzed for eGFP expression. As a result, eGFP expression was observed in all muscles (Figure 11B). From these results, it can be expected that using this system, if Mkl1 or Mkl2 is introduced, expression in muscles can be induced.
[0063] Mice were transfected with the Mkl1 gene via adeno-associated virus (AAV) and analyzed for changes in the expression of Foxo1, Foxo3, and Foxo4 during fasting (Figure 11C). Exogenous expression of Mkl1 suppressed fasting-induced induction of Foxo1 and Foxo3 gene expression. This indicates that Foxo1 and Foxo3 expression is also regulated by Mkl1 in vivo. Since Foxo4 expression did not increase with fasting, the effect of exogenously expressed Mkl1 could not be confirmed. Note that VEH in the figure indicates administration of vehicle only.
[0064] Furthermore, we performed in vivo analysis to determine whether Mkl1 / 2 also had an inhibitory effect on steroid-induced muscle atrophy (Figure 11D). Mkl1 was introduced into the muscles of 9-week-old mice using adeno-associated viruses. 12 weeks later, dexamethasone sodium phosphate was administered intraperitoneally at a concentration of 25 mg / kg. The following day, gastrocnemius muscles were removed and analyzed for expression of the muscle atrophy-causing genes Foxo1, Foxo3, and Foxo4. In vivo, Mkl1 expression suppressed the expression of MuRF1, Foxo1, and Foxo3, and tended to suppress Atrogin-1 and Foxo4. These results demonstrate that Mkl1 expression also has an inhibitory effect on muscle atrophy induced by steroids such as dexamethasone in vivo.
[0065] We investigated whether enhancing Mkl1 / 2 suppresses muscle atrophy and leads to an increase in muscle mass.11 MyoAAV.2A Mhck7-Mkl1 was injected via the tail vein of mice. 12 weeks later, the gastrocnemius muscles were removed and weighed (Fig. 11E). Muscle hypertrophy was visually observed in mice expressing Mkl1, and muscle weight was significantly increased.
[0066] Furthermore, the effects on the heart (myocardium) were analyzed (FIG. 11F). 11 vg, 2 x 10 11 1 × 10 MyoAAV.2A Mhck7-Mkl1 was injected into the tail vein, and the heart was removed 12 weeks later and its weight was analyzed. 11 When the virus was administered at 1000 mg / kg, no difference was observed compared to the PBS-administered control, but when the virus was administered at 2 × 10 11 When administered at 100 mg / kg, myocardial hypertrophy was visible and showed a significant increase in heart weight. It is thought that the myocardial hypertrophy is due to an increase in the number of cardiomyocytes due to cell division as well as an increase in the number of cardiomyocytes themselves.
[0067] These results suggest that the introduction and expression of Mkl1 into muscle using adeno-associated viruses suppressed the expression of muscle atrophy-causing genes and led to hypertrophy of skeletal and cardiac muscles, demonstrating therapeutic efficacy against muscle atrophy. Decreased expression of Mkl1 and Mkl2 has been observed in muscle atrophy due to various causes, including aging, disuse, neurogenic factors, malnutrition, and steroid administration. Therefore, the introduction and expression of Mkl1 and Mkl2 using viral vectors is believed to be therapeutic against muscle atrophy caused by these factors. While Mkl1 / 2 was introduced using adeno-associated viruses, other viral vectors or expression systems may also be used to express Mkl1 / 2 in muscle. Furthermore, because only the TAD, a portion of the Mkl2 protein, can suppress Foxo1 expression, expressing the full length of Mkl1 / 2 is not necessary; expressing the region containing the TAD in muscle is considered to be sufficient for effective treatment.
[0068] Next, we demonstrated that Mkl1 / 2 proteins are rapidly ubiquitinated and degraded. We analyzed whether inhibiting proteasomal degradation could also increase Mkl1 / 2 protein levels. In myotubes induced by differentiation of C2C12 cells, HA-tagged Mkl1 and Mkl2 were expressed using the Tet-On system, and after doxycycline (Dox) removal, changes in intracellular protein levels were analyzed by Western blotting (Figure 12A). Both Mkl1 and Mkl2 have short half-lives, and Mkl1 in particular was shown to be a more unstable protein.
[0069] Therefore, myotubes differentiated from C2C12 cells were treated with MG-132 (FUJIFILM Wako), a ubiquitin-proteasome inhibitor / calpain inhibitor, and the levels of endogenous Mkl1 and Mkl2 were analyzed (Figure 12B). Cells were treated with 10 μM MG-132 for 6 or 12 hours, followed by Western blotting analysis. This stabilized the levels of both Mkl1 and Mkl2 proteins, suggesting that Mkl1 and Mkl2 are constantly degraded by the ubiquitin-proteasome or calpain. Therefore, ubiquitin-proteasome / calpain inhibitors may be effective as pharmaceutical compositions that stabilize Mkl1 and Mkl2 levels and suppress muscle atrophy.
[0070] Because MG-132 inhibits not only the ubiquitin-proteasome but also calpain, analysis was performed using bortezomib, which more specifically inhibits the ubiquitin-proteasome, and Calpain Inhibitor I, which more specifically inhibits calpain (Figure 12C). As described above, C2C12 myotubes were treated with 10 μM MG-132 (FUJIFILM Wako), 10 μM bortezomib (FUJIFILM Wako), or 10 μM Calpain Inhibitor I (Cayman Chemical) for 6 hours, and the levels of Mkl1 and Mkl2 were analyzed by Western blotting. Both Mkl1 and Mkl2 are degraded by the addition of bortezomib, which specifically inhibits ubiquitin proteasome, whereas their degradation is suppressed by calpain inhibitors, suggesting that they are constitutively degraded by calpain. Therefore, calpain inhibitors may be effective as pharmaceutical compositions that stabilize the levels of Mkl1 and Mkl2 and suppress muscle atrophy. The calpain inhibitor used here is not limited to Calpain Inhibitor I, but also includes ALLM, ALLN, Calpain Inhibitor III, Calpain Inhibitor VI, Calpain Inhibitor V, Calpain Inhibitor XI, Calpastatin peptide, Calpetin, EST, PD150606, PD151746, and the like, and can be expected to stabilize Mkl1 and Mkl2 and have the effect of treating muscle atrophy.
[0071] Screening for substances capable of increasing Mkl1 / 2 protein levels can be performed, for example, by exposing cultured cells in which Mkl1 / 2 expression is observed, such as cells established from muscle, to a candidate compound and confirming enhanced Mkl1 / 2 expression. Highly sensitive screening can be performed by creating and introducing a construct fusing a fluorescent protein such as GFP or a reporter protein such as luciferase to the Mkl1 / 2 gene. Alternatively, a reporter gene such as luciferase can be knocked in downstream of the Mkl1 / 2 gene by genome editing to express the fusion protein, and the cells can be exposed to the candidate compound and screened using reporter gene expression as an indicator. After candidate compounds are selected in cells, further compound selection can be performed using cells that can be induced into myotubes or primary myotubes. Furthermore, since steroids such as dexamethasone cause muscle atrophy, animal models in which muscle atrophy is induced by steroids can be used for further investigation. As mentioned above, ubiquitin-proteasome inhibitors have been shown to have the effect of suppressing the degradation of Mkl1 / 2, and therefore drugs that specifically inhibit the degradation of Mkl1 and Mkl2 by the ubiquitin-proteasome are considered to be promising candidates as therapeutic agents for muscle building.
[0072] As described above, calpain inhibitors have been shown to have the effect of specifically inhibiting the degradation of Mkl1 and Mkl2, and therefore, compounds having a specific effect on muscle building may be selected from among calpain inhibitors.
[0073] As described above, the present inventors have discovered new target molecules for muscle atrophy and muscle strengthening. In muscle atrophy, activation of GR and Foxo1 / 3 / 4 induces the expression of muscle atrophy-causing genes. Furthermore, activation of the nuclear receptor GR also induces the expression of Foxo1 and Foxo3. We have demonstrated that Mkl1 and Mkl2 suppress muscle atrophy by inhibiting the transcriptional activity of GR and Foxo1, Foxo3, and Foxo4 (Figure 13). These results suggest that increasing the expression of Mkl1 / 2 can suppress and treat muscle atrophy caused by various causes, for which no effective therapeutic agents have been available until now.
Claims
1. A muscle atrophy inhibitor and / or muscle enhancing agent, characterized in that the target molecules are Mkl1 and / or Mkl2 and the active ingredient is a substance that increases the amount of Mkl1 and / or Mkl2.
2. The muscle atrophy inhibitor and / or muscle enhancing agent according to claim 1, characterized in that the active ingredient increases the amount of Mkl1 and / or Mkl2 in the nucleus.
3. The muscle atrophy inhibitor and / or muscle enhancing agent according to claim 1, characterized in that the muscle atrophy inhibitor is used to treat muscle atrophy caused by aging, disuse, neurogenic causes, malnutrition, or steroid administration.
4. A muscle atrophy inhibitor and / or muscle enhancing agent according to claim 1, characterized in that Mkl1 and / or Mkl2 are introduced by a viral vector.
5. A muscle atrophy inhibitor and / or muscle strengthening agent as described in claim 1, characterized in that the active ingredient increases the amount of Mkl1 and / or Mkl2 by inhibiting the decomposition of Mkl1 and / or Mkl2.
6. The muscle atrophy inhibitor and / or muscle strengthening agent according to claim 5, characterized in that the active ingredient is a calpain inhibitor.
7. A muscle atrophy inhibitor and / or muscle strengthening agent according to any one of claims 1 to 6, characterized in that the muscle is skeletal muscle or cardiac muscle.
8. A method for screening muscle atrophy inhibitors and / or muscle enhancing agents, comprising exposing a candidate compound to cultured cells and using an increase in the amount of Mkl1 and / or Mkl2 in the cultured cells as an indicator.
9. A method for screening muscle atrophy inhibitors and / or muscle enhancing agents according to claim 8, characterized in that a reporter protein is fused to the Mkl1 and / or Mkl2 protein, and an increase in the reporter protein is used as an indicator.
